Favorable first-pass recanalization rates with NeVa™ thrombectomy device in acute stroke patients: Initial clinical experience


Cetin K Akpinar, Atilla O Ozdemir, Erdem Gurkas, Adnan B Bilgic, Ozlem Aykac, Yusuf Inanc, Semih Giray


Interventional Neuroradiology – JULY 2020


The NeVa thrombectomy device (Vesalio LLC, Nashville, USA) has been reported to succeed in large vessel occlusion thrombectomy in animal, in-vitro, and clinical studies. Designed with Drop Zone technology, a closed distal tip, and strong expansive radial force, the device demonstrated particular efficiency in resistant “white” thrombi in preclinical research. Our goal is to determine the safety and performance of this novel stent retriever on first-pass rates and overall recanalization.


The Interventional Neurology Database is a prospectively maintained database of anterior and posterior circulation stroke thrombectomy cases. We retrospectively analyzed cases where the NeVaTM thrombectomy device was used as the first-line treatment strategy. Data collection occurred between January 2019 and January 2020. First-pass recanalization, final recanalization, 90-day functional outcome, complication, and bleeding rates are reported.

  • 118 patients were treated with the NeVa thrombectomy device

  •  The mean patient age was 69+14 years, the median baseline NIHSS was 14, and the median initial ASPECT score was 8

  • The median time from groin puncture to successful recanalization was 29 min (IQR: 20–40)

  • First-pass recanalization rates were 56.8% (mTICI 2b/3) and 44.9% (mTICI 2c/3)

  • Final successful recanalization rate was 95.8% (mTICI 2b/3)

  • Favorable functional outcome (mRS 0–2) was 53% in the “first-pass” subgroup and 42.4% in the total patient population

  • The median number of passes to achieve the final recanalization score was 1 (IQR 1–2)

  • The rate of embolization into new territory was 1.7%. Four patients (3.3%) had symptomatic hemorrhage

  • The NeVa device showed a high rate of “optimal clot integration” and “effective clot removal”


​In our experience, the NeVa device demonstrated high first-pass and overall recanalization rates along with a good safety profile.